OBR Daily Commentary

forumImage

Gene Test To Predict Breast Cancer Recurrence Less Cost Effective In Real World Practice

(GUMC) Jan 8, 2018 - The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by Georgetown Lombardi Comprehensive Cancer Center.

Read Article arrow

Winston Wong, PharmD (Posted: January 10, 2018)

quotes

Very interesting results. Accurately stated, early analysis of OncoTypeDx showed positive cost effectiveness based upon ideal conditions. There is no argument that real world practices paint a more realistic analysis of cost effectiveness. While early studies did note that a portion of the women determined to have high risk of recurrence opted to skip chemotherapy treatment. They also note, as within this study, that a portion of women determined to have a a low risk of recurrence went on to have chemotherapy. What one needs to question is why did these women opt to undergo chemotherapy treatment. In addition, if chemotherapy was part of the treatment plan, why was the test even completed? Also, if chemotherapy was not a treatment option, why was the test completed. I do not disagree with the findings, as they confirm the findings of early studies (if you dig into the detail). So maybe the true action point here is what can be done to refine the inclusion criteria to run the test in the first place. Maybe tests like OncoTypeDc and Prosigna will become much more cost effective if completed in the appropriate population.

quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...